Bioworkshops

About Bioworkshops

Based in Suzhou, China, Bioworkshops operates as a professional biologics contract development and manufacturing organization (CDMO). The company was registered in April 2019 and initiated its first two projects after moving into a new facility in July of the same year. By November 2020, Bioworkshops had successfully passed a QP Audit and obtained the NMPA Drug Manufacturing License.

Bioworkshops provides a comprehensive suite of outsourcing solutions aimed at assisting clients in expediting clinical trials and market entry. The firm's business model is centered on offering end-to-end services for biologic products, particularly focusing on antibodies. Its revenue is generated by providing these development and manufacturing services to other pharmaceutical and biotech companies. The clientele consists of global partners seeking to navigate the regulatory and manufacturing complexities of bringing a biologic drug to market in regions like the USA, EU, and China.

The company's services cover the entire product development lifecycle, from gene sequencing to the final drug product. This includes cell line development, process and analytical development, formulation, and cGMP manufacturing of both drug substances and sterile drug products. Bioworkshops is equipped with advanced single-use bioprocessing facilities, including multiple single-use bioreactor platforms and aseptic filling lines, allowing for high flexibility and production efficiency. Its manufacturing capabilities have expanded significantly, with a total GMP drug substance capacity of 13,000L as of May 2022 and an aseptic filling capacity of 15 million units per year. The company has passed audits for EU QP and US-FDA cGMP compliance, underscoring its commitment to global quality standards.